REG - Medpal AI PLC - Placing to raise £400,000

Medpal AIAnnouncement

01/10/2025 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251001:nRSA7079Ba&default-theme=true

RNS Number : 7079B  Medpal AI PLC  01 October 2025

 

1 October 2025

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

Placing to raise £400,000

 

Further to its announcement today of the acquisition of certain assets from
Universal Pharmacy Ltd (in administration) which can be viewed here News
article | London Stock Exchange
(https://www.londonstockexchange.com/news-article/MPAL/acquisition-of-assets-from-universal-pharmacy-ltd/17259329?showDisclaimer=true)
, MedPal AI (AIM: MPAL), the digital health platform, is pleased to announce
that it has completed a placing of new ordinary shares (the "Placing Shares")
to raise £400,000 for the Company (the "Placing"). The Placing Shares are to
be issued at 8p per share (the "Issue Price"), which represents a discount of
approximately 5.9 per cent. to the mid-market closing price of an Ordinary
Share on 30 September 2025 (being the latest practicable date prior to this
announcement).

 

The proceeds of the Placing and of a WRAP Retail Offer, to be launched shortly
by the Company and announced separately, will be used to progress the
Company's strategy with regard to the recently announced acquisition of assets
from Universal Pharmacy Ltd (in administration), which will enable MedPal AI
to establish itself in the rapidly growing GLP-1 agonist market for obesity
treatment, including drugs such as semaglutide (eg. Ozempic and Mounjaro).

 

For the avoidance of doubt, the Placing is not part of the WRAP Retail Offer
by the Company.

 

The Placing is conditional on the Placing Shares being admitted to trading on
AIM ("Admission"). It is anticipated that Admission will become effective and
that dealings in the Placing Shares will commence on AIM at 8.00 a.m. on 8
October 2025.

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

 

 

 

 MedPal AI plc                       www.medpalplc.com (https://www.medpalplc.com/)

 Jason Drummond

 Cairn Financial Advisers LLP        +44 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited       +44(0) 20 3869 6080

 Bob Roberts

 Winterflood Retail Access Platform  WRAP@winterflood.com

 Sophia Bechev, Kaitlan Billings     +44(0) 20 3100 0214

Further information on the Company can be found on its website at
www.medpalplc.com

 

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

Actual results achieved may vary from the information provided herein as a
result of numerous known and unknown risks and uncertainties and other
factors.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUPGGGUUPAGQG